 |
|
|
|
|
|
|
|
 |
Results for 'RNAi' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
RNAi
Technologies, Markets and Companies
|
September 2008 |
£2010 |
100 % |
RNA Interference Markets
|
September 2008 |
£1340 |
100 % |
RNAi 2004
Strategic Opportunities
|
January 2004 |
£1995 |
98 % |
Future of RNAi Therapeutics, The
Drug Pipelines and Prospects
|
September 2008 |
£1995 |
97 % |
RNAi Therapeutics 2008
|
November 2007 |
£2350 |
97 % |
Outlook for RNAi, 2007
siRNA and miRNA in biology, diagnostics and therapeutics
|
June 2007 |
£1495 |
97 % |
The Exploding RNAi Market & Future Direction
Translating the Genome into a Large Market by 2009
|
February 2001 |
£955 |
95 % |
RNAi, siRNA, microRNA: Industry Background Report
List of Companies
|
October 2005 |
£295 |
94 % |
The Outlook For RNAi
Accelerating drug discovery and the development of RNAi therapeutics
|
January 2005 |
£1495 |
70 % |
Emerging Drug Discovery Technologies
Building competitive advantage through lab-on-a-chip, nanotechnology and RNAi
|
January 2005 |
£1495 |
68.6 % |
RNAi/MicroRNA 2007
|
February 2007 |
£2350 |
35 % |
RNA Interference for Drug R&D
Applications, Alliances, Companies and WW Market to 2011
|
July 2007 |
£1740 |
25.9 % |
Market for RNA Interference Products; The
Challenges and Opportunities
|
October 2004 |
£1880 |
25.55 % |
Worldwide Biotech
June 2005
|
June 2005 |
£17 |
19.95 % |
Lead Optimization Strategies
An analysis of novel molecular targets to develop innovative new therapeutics
|
January 2005 |
£1495 |
17 % |
DNA/RNA Therapies
Translating the Genome into a $1.2bn Market by 2010
|
February 2005 |
£4000 |
14.35 % |
Neurodegenerative Drug Futures
|
February 2005 |
£995 |
11.55 % |
Drug Delivery Systems
US Market Outlook, Advances for Pharma, Biotech & Medical Devices
|
September 2006 |
£1540 |
11.5 % |
High-Content Analysis 2007
|
April 2007 |
£1540 |
10.85 % |
Drug Discovery Tools for High-Content Analysis
|
July 2007 |
£1340 |
10.5 % |
Life Science Tools and Technologies for Bio-Pharma R&D
Instruments, Tech Platforms, Informatics and Market
|
March 2003 |
£1005 |
10 % |
Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts:
The Challenge Of Turning Technology Into Therapy
|
July 2007 |
£1999 |
9.45 % |
Powering Discovery through Target Evaluation
Moving Beyond the Validation Paradigm
|
August 2005 |
£1950 |
8.75 % |
Translational Medicine In Biopharmaceutical R&d
Enabling R&d Optimization And Early Detection Of Potential Failures
|
October 2007 |
£1495 |
7.7 % |
Antiviral Therapeutics
Technologies, Markets and Companies
|
September 2008 |
£1880 |
7.7 % |
Stakeholder Opinions: Respiratory Syncytial Virus (RSV)
A market yet to reach its full potential
|
December 2006 |
£2000 |
7.7 % |
Stakeholder Opinions Respiratory Syncytial Virus (RSV)
A market yet to reach its full potential
|
January 2007 |
£2000 |
7.7 % |
Building Brand Equity in the Molecular Biology Market
|
June 2004 |
£2215 |
7.7 % |
Gene Therapy
Technologies, Markets and Companies
|
September 2008 |
£1435 |
7.5 % |
M&A trends in Pharma
|
October 2008 |
£6000 |
7 % |
The Future of Targeted Therapeutics
Key Technologies, New Therapy Area Applications and Leading Players
|
March 2008 |
£1995 |
6.65 % |
Impact of Genomics on Clinical Trials and Medical Practice, The
|
April 2006 |
£1845 |
6.65 % |
Cancer Personalized Medicine 2008
|
July 2008 |
£2425 |
5.95 % |
Drug Targets for Breast Cancer
|
January 2006 |
£1095 |
5.95 % |
Animal Biotechnology
Technologies, Markets and Companies
|
September 2008 |
£900 |
5.95 % |
Drug Delivery in Central Nervous System Diseases
technologies,markets and companies
|
September 2008 |
£900 |
5.95 % |
Cytogenetics
technologies,markets and companies
|
September 2008 |
£1340 |
5.6 % |
Drug Delivery in Cancer
Technologies, Markets and Companies
|
September 2008 |
£2010 |
4.9 % |
Molecular Diagnostics Markets
|
September 2008 |
£2280 |
4.9 % |
Innovation in Drug Delivery
The future of nanotechnology and non-invasive protein delivery
|
November 2006 |
£1495 |
4.55 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1400 |
4.2 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1400 |
4.2 % |
Cardiovascular Drug Delivery
Technologies, markets and companies
|
September 2008 |
£1475 |
4.2 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1400 |
4.2 % |
Decoding Big Pharmas R&D Strategy in Oncology
|
September 2007 |
£3085 |
4.2 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1400 |
4.2 % |
Biotech Drug Delivery Systems
Key Company Intelligence & Market Outlook to 2012
|
February 2007 |
£1299 |
4.2 % |
Winning R&D Productivity Strategies
Exploiting innovation, licensing and outsourcing opportunities
|
October 2006 |
£1495 |
4.2 % |
Nanotechnology in Health Care to 2009
|
May 2005 |
£2815 |
4.2 % |
The Future Of Array Technologies
Impact on drug discovery and market growth in DNA, protein and tissue arrays
|
January 2005 |
£1495 |
4.2 % |
Novel Targets in Drug Discovery
A new era in therapy
|
April 2004 |
£595 |
3.85 % |
Drug Delivery Technology: Revolutionizing Cardiovascular Therapies
|
July 2007 |
£945 |
3.5 % |
Genomics World Markets
|
May 2008 |
£2280 |
3.5 % |
High Throughput Screening
|
January 2008 |
£2060 |
3.15 % |
The Future of Systems Biology
Emerging technologies and their impact on drug discovery, development and diagnostics
|
January 2005 |
£1495 |
3.15 % |
Molecular Diagnostics
Major World Markets
|
February 2007 |
£2680 |
3.15 % |
Proteomics
Technologies, Markets and Companies
|
September 2008 |
£2345 |
2.8 % |
Global Clinical Trial Business Report & Analysis 2008-2018
|
July 2008 |
£2999 |
2.8 % |
Cell Therapy
Technologies, Markets and Companies
|
September 2008 |
£3020 |
2.45 % |
Medical Nanotechnology Markets
|
September 2008 |
£2280 |
2.45 % |
Neurogenomics and Neurotherapeutic Strategies
New Directions in Platforms, Targets, and Therapeutic Approaches
|
February 2005 |
£1950 |
2.1 % |
Personalized Medicine
scientific & commercial aspects
|
September 2008 |
£2680 |
1.4 % |
Alzheimer disease
new drugs, markets and companies
|
September 2008 |
£1880 |
1.4 % |
|
|
|
|
